Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression.
Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, Sawyers CL, Signoretti S, Hahn WC, Loda M, Sellers WR. Majumder PK, et al. Cancer Cell. 2024 Jun 10;42(6):1126. doi: 10.1016/j.ccell.2024.05.008. Epub 2024 May 30. Cancer Cell. 2024. PMID: 38866454 No abstract available.
Differential Expression of SRY-Related HMG-Box Transcription Factor 2, Oligodendrocyte Lineage Transcription Factor 2, and Zinc Finger E-Box Binding Homeobox 1 in Serum-Derived Extracellular Vesicles: Implications for Mithramycin Sensitivity and Targeted Therapy in High-Grade Glioma.
Patnam S, Majumder B, Joshi P, Singh AD, Nagalla B, Kumar D, Biswas M, Ranjan A, Majumder PK, Rengan AK, Kamath AV, Ray A, Manda SV. Patnam S, et al. Among authors: majumder pk. ACS Pharmacol Transl Sci. 2023 Dec 18;7(1):137-149. doi: 10.1021/acsptsci.3c00198. eCollection 2024 Jan 12. ACS Pharmacol Transl Sci. 2023. PMID: 38230292 Free PMC article.
JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy.
Babu G, Chaudhuri P, Rajappa M, Biswas M, Sansar B, Rajegowda C, Radhakrishnan A, Advani J, Tewary B, Radhakrishnan P, Thiyagarajan S, Chatterjee A, Upadhayaya RS, Majumder PK. Babu G, et al. Among authors: majumder pk. Cancer Biol Ther. 2021 Jan 2;22(1):66-78. doi: 10.1080/15384047.2020.1831371. Epub 2020 Dec 27. Cancer Biol Ther. 2021. PMID: 33356802 Free PMC article.
CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancer.
Bhattacharyya S, Sekar V, Majumder B, Mehrotra DG, Banerjee S, Bhowmick AK, Alam N, Mandal GK, Biswas J, Majumder PK, Murmu N. Bhattacharyya S, et al. Among authors: majumder pk. Cell Oncol (Dordr). 2017 Apr;40(2):145-155. doi: 10.1007/s13402-016-0311-7. Epub 2016 Dec 30. Cell Oncol (Dordr). 2017. PMID: 28039610
Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity.
Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, Brijwani N, Pinto DD, Prasath A, Shanthappa BU, Thayakumar A, Surendran R, Babu GK, Shenoy AM, Kuriakose MA, Bergthold G, Horowitz P, Loda M, Beroukhim R, Agarwal S, Sengupta S, Sundaram M, Majumder PK. Majumder B, et al. Among authors: majumder pk. Nat Commun. 2015 Feb 27;6:6169. doi: 10.1038/ncomms7169. Nat Commun. 2015. PMID: 25721094 Free PMC article.
Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers.
Radhakrishnan P, Baraneedharan U, Veluchamy S, Dhandapani M, Pinto DD, Thiyagarajan S, Thayakumar A, Prasath A, A K, Velu A, Jain M, Brijwani N, Narayanan P, Kekatpure VD, Majumder B, Majumder PK. Radhakrishnan P, et al. Among authors: majumder pk. Cancer Res. 2013 Feb 1;73(3):1118-27. doi: 10.1158/0008-5472.CAN-12-2545. Epub 2013 Jan 29. Cancer Res. 2013. PMID: 23361299
68 results